-
FDA sets May 2027 decision date on AMT-130 gene therapy for HD
4 min read
Latest News
-
Shooting the messenger with single-stranded RNA gene silencing
7 min read
New ‘single-stranded RNA’ gene silencing drugs could be safer & more effective to treat Huntington’s disease
-
EuroBuzz Video: Day 2
18 min read
Watch the full video of EuroBuzz day 2 with Jeff Carroll and Ed Wild at the Euro-HD Network Meeting in Stockholm
-
EuroBuzz Video: Day 1
24 min read
Watch the full video of EuroBuzz day 1 with Jeff Carroll and Ed Wild at the Euro-HD Network Meeting in Stockholm
-
EuroBuzz News: Day 3
3 min read
EuroBuzz news: Day 3. Ed and Jeff reporting from the European Huntington’s Disease Network 2012 meeting in Stockholm
-
EuroBuzz News: Day 2
13 min read
EuroBuzz news: Day 2. Ed and Jeff reporting from the European Huntington’s Disease Network 2012 meeting in Stockholm
-
EuroBuzz News: Day 1
8 min read
EuroBuzz news: Day 1. Ed and Jeff reporting from the European Huntington’s Disease Network meeting in Stockholm
-
Coming Soon: EuroBuzz 2012
2 min read
Coming soon from the Euro-HD Network Meeting in Stockholm: EuroBuzz!
-
Lithium with a twist gets second chance for HD
6 min read
Lithium gets a second chance in HD – with a new chemical delivery method, tested in Huntington’s disease mice
-
High-power brain scans reveal sodium changes in HD
6 min read
A new brain scanning technique reveals high sodium levels in HD brains. How might this help clinical trials?
-
Mapping the neighborhood: huntingtin's new protein partners
7 min read
Study of huntingtin protein's 'neighbors' reveals dozens of new drug development targets
HDBuzz Trial Tracker
FDA accepts BLA for Priority Review, with a target decision date of 1 May 2027.
Show 8 more Show less
Updates from the ongoing Phase 3 INVEST-HD trial of votoplam
Updates from the Phase 1b/2a REGEN4HD trial of neural stem cell therapy hNSC-01
Updates from the ongoing Phase 2/3 FALCON-HD trial of SKY-0515
